Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. — Sponsor Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

8 Recruiting

3 Completed trials

7 Countries active

32 Unique IMPs

100% Results reported

Phase II

Phase III: 1 Phase II: 11 Phase I (Other): 1

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Colorectal cancer metastatic 2 Soft tissue sarcoma 1 Mesothelioma 1 Glioblastoma 1

Top IMPs

AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELLS 4 177LU-PSMA-I&T 2 ALDESLEUKIN 2 PEMBROLIZUMAB 2 (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE 1 BEVACIZUMAB 1 CARBOPLATIN 1 CISPLATIN 1 DEXAMETHASONE PHOSPHATE 1 DEXAMETHASONE SODIUM PHOSPHATE 1 DOCETAXEL 1 ETOPOSIDE 1

All trials

13 total

Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu- edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospect… Pending

2024-519183-40-00 Phase II 1 country LUTETIUM (177LU) EDOTREOTIDE
A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Pa… Pending

2025-524308-31-00 Phase II 2 countries TAMBICICLIB
IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA Recruiting

2024-514517-35-00 Phase III 7 countries
Sequential immunochemotherapy treatment with Pembrolizumab plus Dendritic Cell (DC) Vaccine followed by Trifluridine/Tipiracil plus Bevacizu… Recruiting

2024-514053-30-00 Phase II 1 country AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELLS; BEVACIZUMAB; PEMBROLIZUMAB; TRIF…
A phase II randomized trial of Lu-PSMA and Stereotactic Radiotherapy versus Radiotherapy alone for oligometastatic prostate cancer (LUST) Recruiting

2024-519347-15-00 Phase II 1 country 177LU-PSMA-I&T
68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors (FAPI Basket) Recruiting

2024-511659-17-00 Phase II 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
Phase 2 trial of Translational approach to first line cHemoimmunotherapy followed by maintenance with pembrOlizumab and olaparib in Extensiv… Recruiting

2024-514666-39-00 Phase II 1 country CARBOPLATIN; CISPLATIN; ETOPOSIDE; OLAPARIB; PEMBROLIZUMAB
Vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in Glioblastoma: a phase II Study Recruiting

2024-512493-98-00 Phase II 1 country AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELLS; TEMOZOLOMIDE
A phase II study on adjuvant vaccination with dendritic cells loaded with autologous tumor homogenate in resected stage IV rare cancers: neu… Recruiting

2023-510251-31-00 Phase II 1 country ALDESLEUKIN; AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELLS
Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer… Recruiting

2024-516221-31-00 Phase II 1 country ALDESLEUKIN; AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELLS
Radiometabolic Therapy (RMT) with 177Lu PSMA in PSMA PET/CT positive advanced/metastatic tumours: a basket trial (LUBASKET) Ended

2024-519346-75-00 Phase II 1 country 177LU-PSMA-I&T
Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies Ended

2023-508756-19-00 Phase I (Other) 1 country
Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic cas… Ended

2024-511660-89-00 Phase II 1 country DEXAMETHASONE PHOSPHATE; DEXAMETHASONE SODIUM PHOSPHATE; DOCETAXEL; PREDNISONE; …

Showing 1–13 of 13 trials

← All sponsors A–Z